MECHELEN, BELGIUM--(Marketwired - August 20, 2013) - Galapagos NV (Euronext: GLPG) announced
today the appointment of David Smith as CEO of the service division and
of the Galapagos Executive Committee.
Galapagos' service division comprises BioFocus and Argenta. Together
Fidelta, Galapagos has three leaders in premium drug discovery
pharma, biotech, universities, and patient foundations. Galapagos'
division and Fidelta meet clients' needs for drug discovery tools and
by providing a full range of services, from target discovery through to
of pre-clinical candidates, including compound libraries, medicinal
and ADME/PK services. To further optimize the performance and ensure
growth of this division and Fidelta, a CEO position has been created,
filled by David Smith. Chris Newton, John Montana and Phil Dudfield will
BioFocus, Argenta, and Fidelta, respectively, as Managing Director; they
report to David Smith. David will become member of the Galapagos
Committee and report to Galapagos CEO Onno van de Stolpe.
David Smith joins Galapagos from the Cambridge University Hospitals where
Director Finance for six years. Previously he was CFO of Galapagos
years, during which he played a key role in several M&A projects to
service division between 2005 and 2007. Prior to that, at AstraZeneca he
Marketing Company CFO roles (where he was also a Board member of the
Dutch Holdings Group) and a number of strategic and integration functions
R&D; at Coopers & Lybrand (now PriceWaterhouseCoopers) he was audit manager
variety of industries and international clients in Dubai, and post
as a Chartered Accountant in Leeds he ran a number of
administration. David holds a degree in Molecular Biophysics from
University of Leeds.
"We welcome David back to Galapagos," said Onno van de Stolpe, Chief
Officer, Galapagos. "David brings valuable strategic and operational
to the Galapagos Group, and he is already familiar with the services
from his previous role at the Company. We have confidence that he can
successful Service division to the next level."
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-
with a large pipeline of four clinical, six pre-clinical, and 20
small-molecule and antibody programs in cystic fibrosis,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
of rheumatoid arthritis and potentially other inflammatory diseases,
in Phase 2B studies in RA and about to enter Phase 2 studies in
disease. AbbVie and Galapagos signed a worldwide license agreement
AbbVie will be responsible for further development and commercialization
Phase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 in
and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
2012). GLPG0974 is the first inhibitor of FFA2 to be evaluated
the treatment of IBD; this program is currently in a Proof-of-Concept
study. GLPG1205 is a first-in-class molecule that targets
disorders and is currently in a First-in-Human Phase 1 study.
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has 800 employees and operates facilities in five countries,
global headquarters in Mechelen, Belgium. Further information at:
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
Galapagos appoints David Smith as CEO of Service Division:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE